From Tissue to
Data to Drugs
The Xsphera ex vivo platform, invented at the Dana-Farber Cancer Institute, is a powerful integration of biology and cloud computing that accelerates drug development and guides precision medicine. Our proprietary process enables the simultaneous assessment of multiple therapeutics on a single patient-derived tumor specimen.
Offering Proprietary Science
for Drug Development and Precision Medicine
Unique combination of tumor processing and microfluidics device
Critical to maintaining a complete and viable tumor microenvironment
Validated efficacies for mechanisms of action and mechanisms of resistance
Ready to Learn More?
Procure Tumor Tissue
Qualified clinical sites
- Ensure viability
- Patient & IRB approval
- Strong accrual rate
Process Tissue
Spheroid generation
- Dana-Farber patented process
- Histopathology assessment
- Genomics profiling
Profile Immune and Tumor Cells
- T cells, B cells, NK cells
- Dendritic cells
- Macrophages
- Target expression
Test Treatments
- Load spheroids in ECM per channel
- 3-channels/study arm
- One arm for negative control
- Multiple arms for alternative therapies
Assess Treatments
- Cytotoxicity
- Cytokine expression
- Gene expression
- Automated processes
- Direct to the cloud
Analyze Data
- Per tumor
- Entire study
- Quantified to indicate relative response
- Leverage gene expression to expose MOA & MOR
Interrogate and Explore
- Target identification & verification
- Interactive data analytics
- Automated templates
- Comparisons to standard-of-care studies
Ready to Learn More?
Xsphera Bioscience Preserves the
Tumor Microenvironment for Each Tissue Sample
Check Out More Resources
© 2022 Xsphera Biosciences
6 Tide Street
Boston, MA, 02210 — ALL RIGHTS RESERVED